

**Remarks**

After this amendment claims 1 and 3-7 are pending in the application. Please cancel claim 2 and claims 8-11 without prejudice to further prosecution. Applicant reserves the right to pursue any of the canceled claims in a further application.

Claims 1 stands rejected under 35 U.S.C. 112, first paragraph as allegedly failing to comply with the written description requirement. Claim 1 now recites specific side chain protecting groups useable in the invention. Support for this amendment is found, *inter alia*, at paragraph 29 of the specification. It is believed that now all issues related to written description are rendered moot by this amendment.


**Closing**

It is believed that the presently submitted claims are now in condition for allowance, and that this submission complies with all requirements. But if the Examiner or other PTO personnel have a question or concern that may be resolved quickly with a phone call, said persons are invited to contact the undersigned.

No fees are believed due with the filing of this paper that are not otherwise provided for herein, however, if any fee is or should become due or credit become payable during the pendency of these proceedings, the Examiner is authorized to charge or credit the same to **Deposit Account number 010535.**

Respectfully Submitted,

Dated: Sept. 12, 2008

  
\_\_\_\_\_  
Richard San Pietro  
Registration No. 45,071

AMYLIN PHARMACEUTICALS, INC.  
9360 Towne Centre Drive  
San Diego, CA 92121  
Direct: (858) 754-4981  
Facsimile: (858) 552-1936